Evidence map›Paper›PMID 27992414›Full record

ArticleNature genetics2017

Dynamics of clonal evolution in myelodysplastic syndromes.

Hideki Makishima, Tetsuichi Yoshizato, Kenichi Yoshida, Mikkael A Sekeres, Tomas Radivoyevitch, Hiromichi Suzuki, Bartlomiej Przychodzen, Yasunobu Nagata, Manja Meggendorfer, Masashi Sanada and 27 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature genetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 275 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
275citing papers in PubMed, 1 pooled it
30.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

275 citing papers in PubMed, 1 synthesis or guideline pooled it, 417 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. The global epidemiology of acute myeloid leukaemia.Nature reviews. Clinical oncology · 2026
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

215 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 10 institutions in 4 countries.

Hideki MakishimaDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Tetsuichi YoshizatoDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto, and Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kenichi YoshidaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto, and Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Mikkael A SekeresDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Tomas RadivoyevitchDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Hiromichi SuzukiDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto, and Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Bartlomiej PrzychodzenDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Yasunobu NagataDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto, and Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Manja MeggendorferMLL Munich Leukemia Laboratory, Munich, Germany.
Masashi SanadaClinical Research Center, Nagoya Medical Center, Nagoya, Japan.
Yusuke OkunoDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto, and Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0003-3139-9272
Cassandra HirschDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Teodora KuzmanovicDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Yusuke SatoDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto, and Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Aiko Sato-OtsuboDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto, and Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Thomas LaFramboiseDepartment of Electrical Engineering and Computer Science, Case Western Reserve University, Cleveland, Ohio, USA.
Naoko HosonoDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Yuichi ShiraishiLaboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kenichi ChibaLaboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Claudia HaferlachClinical Research Center, Nagoya Medical Center, Nagoya, Japan.
Wolfgang KernClinical Research Center, Nagoya Medical Center, Nagoya, Japan.
Hiroko TanakaLaboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yusuke ShiozawaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto, and Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Inés Gómez-SeguíDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Holleh D HusseinzadehDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Swapna ThotaDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Kathryn M GuintaDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Brittney DienesDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Tsuyoshi NakamakiDivision of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Shuichi MiyawakiDivision of Hematology, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan.
Yogen SaunthararajahDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Shigeru ChibaDepartment of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Satoru MiyanoLaboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Lee-Yung ShihDivision of Hematology-Oncology, Chang Gung Memorial Hospital-Linkou, Chang Gung University, Taoyuan, Taiwan.
Torsten HaferlachClinical Research Center, Nagoya Medical Center, Nagoya, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto, and Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Jaroslaw P MaciejewskiDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Cleveland Clinic · USKyoto University · JPNagoya Medical Center · JPThe University of Tokyo · JPCase Western Reserve University · USChang Gung University · TWMunich Leukemia Laboratory (Germany) · DEShowa University · JPTokyo Metropolitan Ohtsuka Hospital · JPUniversity of Tsukuba · JP

Funding

BONE MARROW FAILURE CLINICAL RESEARCH CENTERU54RR019397 · NCRR · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P. · 2003 to 2008
$5.3M
Investigations of Consequences of U2AF1 Mutations in MDSR01HL118281 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P., PADGETT, RICHARD A · 2013 to 2017
$1.9M
Predisposition to chromosomal alterations in MDSR01HL082983 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P. · 2005 to 2008
$1.5M
Training/Research Center-Bone Marrow Failure SyndromesK24HL077522 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P. · 2005 to 2014
$1.2M
LASER SCANNING CONFOCAL MICROSCOPE: NEUROSCIENCES10RR019391 · NCRR · UNIVERSITY OF LOUISVILLE · PI CHENG, ZIXI JACK · 2004 to 2004
$315k
NCRR NIH HHS S10 RR019391NCRR NIH HHS U54 RR019397NHLBI NIH HHS K24 HL077522NHLBI NIH HHS R01 HL082983
6 · The paper itself

Abstract

To elucidate differential roles of mutations in myelodysplastic syndromes (MDS), we investigated clonal dynamics using whole-exome and/or targeted sequencing of 699 patients, of whom 122 were analyzed longitudinally. Including the results from previous reports, we assessed a total of 2,250 patients for mutational enrichment patterns. During progression, the number of mutations, their diversity and clone sizes increased, with alterations frequently present in dominant clones with or without their sweeping previous clones. Enriched in secondary acute myeloid leukemia (sAML; in comparison to high-risk MDS), FLT3, PTPN11, WT1, IDH1, NPM1, IDH2 and NRAS mutations (type 1) tended to be newly acquired, and were associated with faster sAML progression and a shorter overall survival time. Significantly enriched in high-risk MDS (in comparison to low-risk MDS), TP53, GATA2, KRAS, RUNX1, STAG2, ASXL1, ZRSR2 and TET2 mutations (type 2) had a weaker impact on sAML progression and overall survival than type-1 mutations. The distinct roles of type-1 and type-2 mutations suggest their potential utility in disease monitoring.

Indexed as

Clonal EvolutionClone CellsDisease ProgressionExomeHumansLeukemia, Myeloid, AcuteMutationMyelodysplastic SyndromesNucleophosminNucleophosmin

Identifiers

PMID27992414
PMCPMC8210656
OpenAlexW2561161989

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.